67. Paroxetine methanesulfonate in crystalline form having a melting point of 147°C to 148°C.

68. Paroxetine methanesulfonate in crystalline form having a melting point of 146°C to 147°C.

69. Paroxetine methanesulfonate in crystalline form having a melting point of 145°C to 146°C.

70. A method of treating or preventing a disease state selected from: depression, panic disorder, pre-menstrual syndrome, anxiety, obsessive compulsive disorder, social phobia and adolescent depression, which comprises administering an effective or prophylactic amount of paroxetine methanesulfonate, as described in claim 64.

71. A method of treating or preventing a disease state selected from: depression, panic disorder, pre-menstrual syndrome, anxiety, obsessive compulsive disorder, social phobia and adolescent depression, which comprises administering an effective or prophylactic amount of paroxetine methanesulfonate, as described in claim 65.

B1

72. A method of treating or preventing a disease state selected from: depression, panic disorder, pre-menstrual syndrome, anxiety, obsessive compulsive disorder, social phobia and adolescent depression, which comprises administering an effective or prophylactic amount of paroxetine methanesulfonate, as described in claim 66.

73. A method of treating or preventing a disease state selected from: depression, panic disorder, pre-menstrual syndrome, anxiety, obsessive compulsive disorder, social phobia and adolescent depression, which comprises administering an effective or prophylactic amount of paroxetine methanesulfonate, as described in claim 67.

74. A method of treating or preventing a disease state selected from: depression, panic disorder, pre-menstrual syndrome, anxiety, obsessive compulsive disorder, social phobia and adolescent depression, which comprises administering an effective or prophylactic amount of paroxetine methanesulfonate, as described in claim 68.

75. A method of treating or preventing a disease state selected from: depression, panic disorder, pre-menstrual syndrome, anxiety, obsessive compulsive disorder, social phobia and adolescent depression, which comprises administering an effective or prophylactic amount of paroxetine methanesulfonate, as described in claim 69.

76. A pharmaceutical composition comprising a compound according to claim 64 and a pharmaceutically acceptable carrier.

77. A composition according to claim 76 in which the carrier comprises a binder.

78. A composition according to claim 76 in which the carrier comprises a colouring agent.

79. A composition according to claim 76 in which the carrier comprises a flavouring agent.

80. A composition according to claim 76 in which the carrier comprises a preservative.

81. A composition according to claim 76 adapted for oral administration.

82. A composition according to claim 81 which is a tablet or capsule.

83. A composition according to claim 82 which is a modified oval shaped tablet.

84. A composition according to claim 76 comprising 1 to 200mg of active ingredient, calculated on a free base basis.

85. A compound according to claim 64 having *inter alia* the following characteristic IR peaks: 1603, 1513, 1194, 1045, 946, 830, 776, 601, 554, and 539 ± 4 cm-1; and/or the following characteristic XRD peaks: 8.3, 10.5, 15.6, 16.3, 17.7, 18.2, 19.8, 20.4, 21.5, 22.0, 22.4, 23.8, 24.4, 25.0, 25.3, 25.8, 26.6, 30.0, 30.2, and 31.6 ±0.2 degrees 2 theta.

86. A method of treating or preventing a disease state selected from: depression, panic disorder, pre-menstrual syndrome, anxiety, obsessive compulsive disorder, social phobia and adolescent depression, which comprises administering an effective or prophylactic amount of paroxetine methanesulfonate in crystalline form having the following characteristic IR peaks: 1603, 1194, 1045, 946, 830, 601, 554, and 539 ± 4 cm-1.

87. A method of treating or preventing a disease state selected from: depression, panic disorder, pre-menstrual syndrome, anxiety, obsessive compulsive disorder, social phobia and adolescent depression, which comprises administering an effective or prophylactic amount of paroxetine methanesulfonate, as described in claim 85.

88. A pharmaceutical composition comprising a compound according to claim 85 and a pharmaceutically acceptable carrier.

89. A composition according to claim 85 in which the carrier comprises a binder.

90. A composition according to claim 85 in which the carrier comprises a colouring agent.

91. A composition according to claim 85 in which the carrier comprises a flavouring agent.

92. A composition according to claim 85 in which the carrier comprises a preservative.

93. A composition according to claim 85 adapted for oral administration.

94. A composition according to claim 93 which is a tablet or capsule.

95. A composition according to claim 94 which is a modified oval shaped tablet.

96. A composition according to claim 85 comprising 1 to 200mg of active ingredient, calculated on a free base basis.

97. A pharmaceutical composition adapted for oral administration comprising per unit dose 10, 12.5, 15, 20, 25, 30 or 40 mg, calculated on a free base basis, of paroxetine methanesulfonate in crystalline form and having the following characteristic IR peaks: 1603, 1194, 1045, 946, 830, 601, 554, and 539 ± 4 cm^{-1}, and a pharmaceutically acceptable carrier.

98. A compound according to claim 64 having *inter alia* the following characteristic IR peaks: 1603, 1513, ~~1194~~, 1045, 946, 830, 776, 601, 554 and 539 cm-1; and/or the following characteristic XRD peaks: 8.3, 10.5, 15.6, 16.3, 17.7, 18.2, 19.8, 20.4, 21.5, 22.0, 22.4, 23.8, 24.4, 25.0, 25.3, 25.8, 26.6, 30.0, 30.2 and 31.6.

99. A method of treating or preventing a disease state selected from: depression, panic disorder, pre-menstrual syndrome, anxiety, obsessive compulsive disorder, social phobia and adolescent depression, which comprises administering an effective or prophylactic

amount of paroxetine methanesulfonate in crystalline form having the following characteristic IR peaks: 1603, 1194, 1045, 946, 830, 601, 554 and 539 cm-1.

100. A method of treating or preventing a disease state selected from: depression, panic disorder, pre-menstrual syndrome, anxiety, obsessive compulsive disorder, social phobia and adolescent depression, which comprises administering an effective or prophylactic amount of paroxetine methanesulfonate, as described in claim 98.

101. A pharmaceutical composition comprising a compound according to claim 98 and a pharmaceutically acceptable carrier.

102. A composition according to claim 98 in which the carrier comprises a binder.

103. A composition according to claim 98 in which the carrier comprises a colouring agent.

104. A composition according to claim 98 in which the carrier comprises a flavouring agent.

105. A composition according to claim 98 in which the carrier comprises a preservative.

106. A composition according to claim 98 adapted for oral administration.

107. A composition according to claim 106 which is a tablet or capsule.

108. A composition according to claim 107 which is a modified oval shaped tablet.

109. A composition according to claim 97 comprising 1 to 200mg of active ingredient, calculated on a free base basis.

110. A pharmaceutical composition adapted for oral administration comprising per unit dose 10 mg, calculated on a free base basis, of paroxetine methanesulfonate in crystalline form and having the following characteristic IR peaks: 1603, 1194, 1045, 946, 830, 601, 554, and 539 cm^{-1}, and a pharmaceutically acceptable carrier.

111. A pharmaceutical composition adapted for oral administration comprising per unit dose 20 mg, calculated on a free base basis, of paroxetine methanesulfonate in crystalline